Every 8-K that Cumberland Pharmaceuticals Inc (CPIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPIX filings page.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reports that its Board of Directors has set the frequency of advisory shareholder votes on compensation of the Company’s named executive officers at every three years, following the 2026 Annual Meeting where the three-year option received the highest number of votes.
The Board states that these advisory votes will occur every three years until the next required shareholder advisory vote on the frequency of future executive compensation votes, which must be held every six years.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reported under Regulation FD that long-term safety and efficacy data from the ongoing open-label extension of its Phase 2 FIGHT DMD trial of ifetroban for Duchenne muscular dystrophy–related heart disease are not yet available.
The company had previously indicated this extension data was expected in August 2026 but now states it no longer expects to present the data in August 2026 and plans to present it at a future date when available. Cumberland also reiterates that forward-looking statements are subject to various risks and uncertainties described in its SEC filings.
Cumberland Pharmaceuticals Inc. reported results for the three and six months ended June 30, 2026 and described a major strategic shift following the closing of its Strategic Transaction with Apotex Health. Apotex acquired Cumberland’s portfolio of FDA-approved brands and related commercial organization for $100 million in cash at closing, plus $11 million in funding for inventory and transition services, as Cumberland transitions to a development-stage biopharmaceutical company focused on rare diseases and other unmet needs.
The Board declared a $1.50 per-share special cash dividend, paid July 31, 2026 to shareholders of record July 23, 2026, after determining the company would retain significant liquidity for its pipeline and operations. For Q2 2026, the loss from continuing operations was $3.1 million, and including discontinued operations the net loss was $4.1 million.
At June 30, 2026, total assets were $62.9 million, including $3.9 million in cash and cash equivalents, with liabilities of $45.8 million and shareholders’ equity of $17.4 million$5.2 million payment and continues to advance four Phase 2 ifetroban programs, including updated Duchenne muscular dystrophy and cancer metastasis data.
Cumberland Pharmaceuticals Inc. authorized and declared a special cash dividend of $1.50 per share on its common stock, payable on or about July 31, 2026 to shareholders of record at the close of business on July 23, 2026. The board also approved a new open‑market share repurchase program authorizing up to $5 million of common stock over time, replacing the prior authorization.
These capital return actions follow a strategic transaction with Apotex Health Corp., under which Cumberland received $100 million in cash at closing for its line of FDA‑approved products and expects up to an additional $11 million tied to product inventory and transitional support services. After tax analysis and updated financial projections indicated greater net cash than first projected, the board assessed future cash needs and designated excess capital for the dividend and repurchase, while several directors plan new share purchase arrangements.
Cumberland retains its portfolio of product candidates and majority stake in Cumberland Emerging Technologies Inc. and will focus resources on late‑stage development of ifetroban for serious rare diseases, including Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and high‑risk solid tumors, supported by multiple Phase II studies and U.S. FDA designations.
Cumberland Pharmaceuticals has closed a strategic asset sale to Nuvo Pharmaceuticals and Apotex affiliates, receiving cash consideration of $100 million for its FDA‑approved branded products, including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ, plus related equity interests.
The company used part of the proceeds to terminate and fully repay about $5.3 million outstanding under its revolving credit agreement, releasing associated liens. Pro forma as of March 31, 2026, cash and cash equivalents rise to roughly $110.2 million, with shareholders’ equity increasing to about $81.4 million, while the disposed operations will be treated as discontinued operations.
Cumberland is retaining its ifetroban product candidates and majority stake in Cumberland Emerging Technologies, and will focus on late‑stage development programs in rare and serious diseases including Duchenne muscular dystrophy, systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis.
Cumberland Pharmaceuticals Inc. held a special meeting of shareholders to vote on a proposal tied to a strategic transaction with Apotex Inc. involving the company’s FDA-approved commercial products and related assets.
Shareholders approved authorizing and approving the asset sale, which may be deemed under Tennessee law to be a sale of substantially all of the company’s property and assets outside the usual course of business. Of 14,983,107 common shares entitled to vote as of the record date, 10,509,626 were present, representing a 70.14% quorum. The proposal received 10,492,455 votes in favor, 15,904 against, and 1,267 abstentions, meaning 70.03% of all outstanding shares and 99.84% of votes cast supported the transaction.
Cumberland Pharmaceuticals reported first quarter 2026 net revenues of $9.1 million, with management noting this was a 5% increase versus the prior year period after excluding a $3 million milestone received in 2025. The quarter ended with total assets of $71.0 million, liabilities of $49.7 million and shareholders’ equity of $21.6 million.
The company recorded a net loss of $3.3 million, or $0.22 per shareadjusted loss of $1.9 million, or $0.13 per share. Total operating expenses were $12.3 million.
Cumberland also highlighted a pending Strategic Transaction with Apotex, under which Apotex will acquire Cumberland’s portfolio of FDA‑approved brands for $100 million in cash, subject to shareholder approval and customary conditions. Cumberland will retain its ifetroban development programs and its majority interest in Cumberland Emerging Technologies, positioning the company as a development‑stage biopharmaceutical organization focused on orphan and other high‑value candidates.
Cumberland Pharmaceuticals Inc. reported the results of its annual shareholder meeting held in Nashville, Tennessee on April 21, 2026. Shareholders elected Class I directors Kenneth J. Krogulski and Caroline R. Young, each receiving over 98% of votes cast, with Krogulski supported by 9,561,336 votes and Young by 9,479,023 votes.
Shareholders also ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for the year ending December 31, 2026, with 12,714,116 votes in favor. An advisory vote approved the compensation of named executive officers, and another advisory vote indicated a strong preference to hold this say‑on‑pay vote every three years, supported by 7,844,848 votes.
Cumberland Pharmaceuticals agreed to sell the assets tied to its U.S. branded commercial products to an Apotex affiliate for $100,000,000 in cash at closing under an Asset Purchase Agreement. The assets include Cumberland’s FDA‑approved brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ, plus certain product-related equity interests.
Cumberland will retain its ifetroban pipeline programs and majority stake in Cumberland Emerging Technologies and plans to focus on these orphan and specialty development candidates after closing. The deal requires approval by holders of a majority of outstanding shares and other customary conditions, with a long-stop date of August 20, 2026.
Both parties agreed to $4,000,000 termination fees in specified circumstances, as well as non‑solicitation, non‑competition and non‑interference covenants for up to four years. Voting and support agreements cover about 41% of outstanding shares, and a financial advisor delivered a fairness opinion stating the consideration is fair and reasonable from a financial point of view.
Cumberland Pharmaceuticals reported strong 2025 growth with improving profitability and cash generation. Net revenues reached $44.5 million for 2025, up 18% year over year, including $13.7 million in fourth-quarter revenue, a 31% increase over the prior-year quarter. Key brands contributed $10.5 million from Kristalose, $11.9 million from Sancuso, $9.5 million from Vibativ, $4.7 million from Caldolor and $3.3 million from Talicia.
The company’s 2025 net loss narrowed to $2.9 million, a $3.6 million improvement from 2024, while Adjusted Earnings were $1.7 million, a $2.7 million improvement. Operating cash flow turned positive at $4.9 million. At December 31, 2025, Cumberland reported $76.8 million in total assets, $52.3 million in liabilities and $24.9 million in shareholders’ equity, including $11.4 million in cash and a reduced credit facility balance of $5.2 million, down $10 million from year-end 2024.
Strategically, Cumberland expanded Vibativ into China and Saudi Arabia, gained approval for an ibuprofen injection in Mexico, and added Talicia via a co-commercialization agreement. Caldolor received a permanent CMS J-code (J1741), and the ifetroban FIGHT DMD Phase II trial delivered positive top-line results, with the DMD program receiving Orphan Drug, Rare Pediatric Disease and Fast Track designations.
Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD). This status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. Cumberland furnished a press release with additional details as an exhibit to this report.
Cumberland Pharmaceuticals Inc. entered into an amendment to its revolving credit arrangements with Pinnacle Bank. The amendment keeps the aggregate principal funding available at up to $25 million, with $15 million currently available for borrowing and the right for Cumberland to request an additional $10 million. The revolving line continues to be secured by substantially all of the company’s assets.
The facility includes a quarterly-tested Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements. Borrowings will bear interest at Benchmark Term SOFR plus 2.75%. The amendment also extends the credit facility’s maturity to October 1, 2027, giving Cumberland a longer-dated source of revolving liquidity.
Cumberland Pharmaceuticals Inc. filed a current report to furnish a press release dated November 4, 2025. The press release provides a company update and the financial results for the three and nine months ended September 30, 2025. The information is furnished under Item 2.02 regarding results of operations and financial condition and is not deemed filed for liability purposes under Section 18 of the Exchange Act unless later specifically incorporated by reference.
Cumberland Pharmaceuticals (CPIX) reported a strategic arrangement with RedHill Biopharma to jointly commercialize Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults. The product targets a bacterial infection that is a leading risk factor for gastric cancer.
The company furnished a related press release as Exhibit 99.1 dated October 21, 2025. This update was disclosed under Item 8.01 (Other Events).